June 23, 2014
Hokkaido University announced on June 17 that it will initiate an independent clinical study of its novel injectable cancer diagnostic imaging agent [ 123 I] 5-iodo-6-[(2-iminoimidazolidinyl) methyl] uracil ([ 123 I] IIMU) to evaluate its safety. This will be the...read more